The aim of the clinical trial in the patients with lung cancer treated by combined radiotherapy and chemotherapy was to prospectively observe the effect of jiaogulan on the cellular immunity and prognossis. The results: cellular immunity of the control groups was further suppressed; when the patients take jiaogulan tables (180-240mg/day) during the therapy period (60 days) the immune situation could keep no change. Comparing the jiaogulan group with the control group after a year, although there were no significant differences in statistics onthe distant metastatic rate, the medial time of distant metastasis and the local tumor control rate and survival rate 6 and 12 months respectively, but the trend that the prognosis of the superior to the latter could be found. The results show that jiaogulan can protect patient^s cellular immunity when the patients receiving radiotherapy plus chemotherapy.